Inclusion Criteria:

          -  Confirmed histologic diagnosis of prostate cancer and have mCRPC

          -  Prior therapies defined as at least 2 prior lines of systemic therapy for prostate
             cancer, including at least one second generation androgen receptor inhibitor and/or
             CYP17α inhibitor. At least one line of prior therapy must be in the mCRPC setting

          -  Evidence of disease as defined as castrate levels of testosterone (<50 ng/mL) AND
             Evidence of one of the following measures of progressive disease in the 12 weeks
             preceding eligibility confirmation by physician: i.) Soft tissue progression by
             Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; ii.) Osseous
             disease progression with 2 or more new lesions on bone scan; iii.) Increase in serum
             PSA of at least 25% and an absolute increase of 2 ng/mL or more from nadir on at least
             three consecutive tests a minimum of 1 week apart

          -  PSMA+ disease determined by centrally tested PSMA expression in prior or archival
             tumor sample

          -  Evaluable disease per Prostate Working Group 3 (PCWG3) criteria

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

          -  Life expectancy of greater than 3 months

          -  Toxicities from any previous therapy must have recovered to Grade 1 or baseline

          -  Patients who have not undergone bilateral orchiectomy must be able to continue
             gonadotropin-releasing hormone (GnRH) therapy during the study

          -  Estimated creatinine clearance ≥ 60 mL/min by Modification of Diet in Renal Disease
             criteria

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5x the upper
             limit of normal (ULN); patients with hepatic metastases ALT and AST ≤ 3.0 x ULN

          -  Serum total bilirubin < 1.5 mg/dL unless patient has known Gilbert's Syndrome, then
             serum bilirubin ≤3 mg/dL

          -  Serum albumin ≥ 3.0 g/dL

          -  Left ventricular ejection fraction (LVEF) ≥ 50%. LVEF assessment must have been
             performed within 8 weeks of enrollment

          -  Hemoglobin ≥ 9 g/dL

          -  Absolute neutrophil count ≥ 1500/μL

          -  Platelet count ≥ 100,000/μL

          -  Patients of reproductive potential agree to use of approved highly effective
             contraceptive methods

        Exclusion Criteria:

          -  Active invasive cancer, other than the proposed cancer included in the study, within 2
             years prior to screening, unless treated with curative intent

          -  Current treatment with systemic corticosteroids (defined as a dose greater than the
             equivalent of prednisone 10 mg/day)

          -  Active autoimmune disease (including connective tissue disease, uveitis, sarcoidosis,
             inflammatory bowel disease or multiple sclerosis) or a history of severe autoimmune
             disease requiring prolonged immunosuppressive therapy (any immunosuppressive therapy
             within 6 weeks prior to screening visit)

          -  Current, active human immunodeficiency virus (HIV), hepatitis C virus, hepatitis B
             virus infections

          -  Prior allogeneic stem cell transplant

          -  Active and untreated central nervous system malignancy

          -  History of severe infusion reaction to monoclonal antibodies or biological therapies,
             or to study product excipients that would preclude the patient safely receiving
             CART-PSMA-TGFβRDN cells

          -  History of being previously treated with a J591 antibody-based therapy

          -  Active or recent (within the past 6 months prior to apheresis) cardiac disease,
             defined as (1) New York Heart Association Class III or IV heart failure, (2) unstable
             angina or (3) a history of recent (within 6 months) myocardial infarction or sustained
             (> 30 second) ventricular tachyarrhythmias

          -  Have inadequate venous access for or contraindications for the apheresis procedure

          -  Must agree not to participate in a conception process or must agree to a highly
             effective method of contraception